GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beijing Tiantan Biological Products Corp 600161.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

12.51

-1.26%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥6.14bn

FY2016FY2025

Net income

CN¥1.09bn

FY2016FY2025

Free cash flow

−CN¥229.6m

FY2016FY2025

Shareholders' equity

CN¥11.74bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥6.14bnCN¥6.03bnCN¥5.18bnCN¥4.26bnCN¥4.11bnCN¥3.45bnCN¥3.28bnCN¥2.93bnCN¥2.48bnCN¥2.14bn
Gross profitCN¥2.58bnCN¥3.29bnCN¥2.63bnCN¥2.09bnCN¥1.95bnCN¥1.70bnCN¥1.62bnCN¥1.37bnCN¥1.27bnCN¥1.11bn
Research and developmentCN¥147.7mCN¥173.3mCN¥139.9mCN¥122.0mCN¥133.2mCN¥119.9mCN¥118.7mCN¥105.4mCN¥94.3mCN¥142.5m
Operating incomeCN¥1.77bnCN¥2.56bnCN¥1.80bnCN¥1.43bnCN¥1.24bnCN¥1.10bnCN¥1.05bnCN¥868.4mCN¥772.2mCN¥446.2m
Net incomeCN¥1.09bnCN¥1.55bnCN¥1.11bnCN¥880.9mCN¥760.0mCN¥639.0mCN¥611.1mCN¥509.5mCN¥1.17bnCN¥256.9m
Diluted earnings per share0.550.780.670.530.440.510.500.410.940.21

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥16.64bnCN¥15.87bnCN¥14.19bnCN¥12.94bnCN¥11.58bnCN¥7.54bnCN¥6.31bnCN¥5.07bnCN¥3.67bnCN¥5.78bn
Cash and short-term investmentsCN¥1.99bnCN¥2.69bnCN¥4.55bnCN¥3.71bnCN¥4.33bnCN¥1.75bnCN¥1.41bnCN¥1.25bnCN¥1.76bnCN¥660.3m
Total liabilitiesCN¥1.22bnCN¥1.34bnCN¥1.43bnCN¥1.58bnCN¥1.31bnCN¥1.51bnCN¥1.14bnCN¥720.2mCN¥481.5mCN¥3.34bn
DebtCN¥187.3mCN¥44.9mCN¥24.4mCN¥403.2mCN¥508.9mCN¥801.0mCN¥400.6mCN¥230.8mCN¥200.0mCN¥2.34bn
Shareholders' equityCN¥11.74bnCN¥11.14bnCN¥9.82bnCN¥8.80bnCN¥8.05bnCN¥4.52bnCN¥3.94bnCN¥3.37bnCN¥3.04bnCN¥2.19bn
Shares outstanding1,977m1,986m1,648m1,648m1,715m1,254m1,223m1,251m1,255m1,245m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥375.9mCN¥819.8mCN¥2.39bnCN¥1.13bnCN¥980.4mCN¥702.1mCN¥642.5mCN¥677.9mCN¥218.4mCN¥428.4m
Capital spending−CN¥605.5m−CN¥1.07bn−CN¥1.08bn−CN¥1.35bn−CN¥1.13bn−CN¥608.9m−CN¥526.2m−CN¥293.9m−CN¥144.9m−CN¥209.4m
Free cash flow−CN¥229.6m−CN¥247.6mCN¥1.32bn−CN¥228.0m−CN¥151.3mCN¥93.2mCN¥116.2mCN¥384.0mCN¥73.5mCN¥219.0m
Dividends paid−CN¥494.3m−CN¥247.2m−CN¥82.4m−CN¥137.3m−CN¥137.3m−CN¥62.7m−CN¥43.6m−CN¥140.1m−CN¥186.4m−CN¥100.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.45bnCN¥1.14bnCN¥1.70bnCN¥1.34bnCN¥1.79bnCN¥1.32bnCN¥1.96bnCN¥1.23bn
Gross profitCN¥539.2mCN¥394.9mCN¥723.4mCN¥525.5mCN¥800.6mCN¥604.5mCN¥1.04bnCN¥673.4m
Operating incomeCN¥322.4mCN¥214.8mCN¥470.7mCN¥302.8mCN¥635.7mCN¥406.2mCN¥831.2mCN¥535.0m
Net incomeCN¥173.0mCN¥125.9mCN¥272.2mCN¥186.1mCN¥388.4mCN¥244.1mCN¥497.4mCN¥325.6m
Diluted earnings per share0.090.060.140.090.200.120.250.16
Cash from operations——CN¥221.0mCN¥318.0mCN¥99.0m−CN¥301.0m—CN¥92.0m
Capital spending−CN¥154.0m−CN¥187.0m−CN¥155.0m−CN¥125.0m−CN¥181.0m−CN¥144.0m−CN¥333.0m−CN¥186.0m
Free cash flow——CN¥66.0mCN¥193.0m−CN¥82.0m−CN¥445.0m—−CN¥94.0m
Total assetsCN¥17.05bnCN¥16.68bnCN¥16.64bnCN¥16.55bnCN¥16.52bnCN¥16.24bnCN¥15.87bnCN¥15.55bn
Cash and short-term investments——CN¥1.99bnCN¥1.90bnCN¥1.90bnCN¥2.28bnCN¥2.69bnCN¥4.80bn
Debt——CN¥119.3mCN¥160.7mCN¥17.4mCN¥35.0m——
Shareholders' equityCN¥11.94bnCN¥11.86bnCN¥11.74bnCN¥11.46bnCN¥11.57bnCN¥11.38bnCN¥11.14bnCN¥10.64bn

Financial ratios

Data as of 22 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin42.0%54.6%50.7%49.0%47.5%49.2%——
Operating margin28.8%42.4%34.8%33.6%30.3%32.1%——
Net margin17.8%25.7%21.4%20.7%18.5%18.5%——
Return on equity9.3%13.9%11.3%10.0%9.4%14.1%——
Return on assets6.6%9.8%7.8%6.8%6.6%8.5%——
Free cash flow yield4.0%7.6%16.9%12.1%9.9%8.4%——
Revenue growth1.8%16.4%21.6%3.6%19.3%5.0%——
Earnings growth-29.6%39.6%26.0%15.9%18.9%4.6%——
Current ratio8.00x6.89x5.92x6.28x9.32x4.96x——
Debt to equity0.01x——0.04x0.05x0.15x0.10x0.07x
Equity ratio70.5%70.2%69.2%68.0%69.5%59.9%——
Interest coverage176.70x323.98x300.76x350.81x402.97x258.64x——
R&D as a share of sales2.4%2.9%2.7%2.9%3.2%3.5%——
Buybacks as a share of market value0.4%-20.5%0.0%3.9%-36.8%-2.5%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.9%12.2%14.3%
Operating income7.2%9.8%25.5%
Net income7.4%11.3%59.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin48.2%49.0%48.8%48.8%
Operating margin35.5%35.0%34.0%31.8%
Net margin21.7%21.4%20.7%20.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings29.626.338.337.045.456.832.425.111.454.5
Price to sales5.36.88.27.78.410.56.04.45.46.5

Dividends and splits

Per share, in the currency the company pays

Paid for 9 years. Last went ex-dividend on 23 Sept 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.150.250.150.0420.0830.0690.0420.024
  • 6-for-5 split · 20 Jun 2024
  • 6-for-5 split · 15 Jul 2022
  • 6-for-5 split · 15 Jul 2020
  • 6-for-5 split · 14 Jun 2019
  • 13-for-10 split · 22 Jun 2018
  • 13-for-10 split · 19 Jun 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.